Clinical efficacy of a new 30-min algorithm for transurethral microwave thermotherapy: initial results

Citation
Jjmch. De La Rosette et al., Clinical efficacy of a new 30-min algorithm for transurethral microwave thermotherapy: initial results, BJU INT, 86(1), 2000, pp. 47-51
Citations number
27
Categorie Soggetti
Urology & Nephrology
Journal title
BJU INTERNATIONAL
ISSN journal
14644096 → ACNP
Volume
86
Issue
1
Year of publication
2000
Pages
47 - 51
Database
ISI
SICI code
1464-4096(200007)86:1<47:CEOAN3>2.0.ZU;2-O
Abstract
Objective To assess the efficacy of a new 30-min algorithm for high-energy transurethral microwave thermotherapy (TUMT, Prostasoft 3.5) in the treatme nt of men with lower urinary tract symptoms (LUTS) caused by benign prostat ic hyperplasia. Patients and methods A total of 108 men (mean age 66 years) with bothersome LUTS were treated with the new TUMT protocol. All patients were evaluated using a standard assessment at baseline, 6, 12, 26 and 52 weeks after TUMT. The evaluation included the assessment of objective and subjective outcome measures, with a urodynamic evaluation using pressure-flow analysis, and t he occurrence of adverse events. Results The treatment was well tolerated. In general, the International Pro state Symptom Score improved from a mean of 20.0 at baseline to a mean of 9 .3 at 6 months after treatment. The maximum urinary flow improved from 9.4 mL/s to 14.6 mL/s at 6 months. The mean duration of catheterization was 17. 9 days. The urodynamic evaluation showed a change from the obstructed to th e equivocal zone on the Abrams-Griffith nomogram. There were no serious com plications. Urgency and frequency were the most frequent side-effects after treatment: these all resolved within 3 months. Conclusion High-energy TUMT using the new high-dose Prostasoft 3.5 protocol appears to be a safe and effective treatment. The faster procedure improve s the tolerance of the treatment. The subjective and objective improvements were significant and the treatment-related morbidity low. A longer follow- up is needed to assess the durability of this new treatment protocol.